title: National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
abstract: OBJECTIVE
  In 2012, the US Preventive Services Task Force (USPSTF) discouraged prostate-specific antigen (PSA) -based prostate cancer screening. Previous USPSTF recommendations did not appreciably alter prostate cancer screening. Therefore, we designed a trend analysis to determine the population-based impact of the 2012 recommendation.
  
  
  METHODS
  The nationally representative National Health Interview Survey was used to estimate the proportion of men age 40 years and older who saw a physician and were screened for prostate cancer in 2013. An externally validated 9-year mortality index was used to analyze screening rates based on remaining life expectancy. Screening rates from 2005, 2010, and 2013 were compared using logistic regression.
  
  
  RESULTS
  PSA-based screening did not significantly change from 2010 to 2013 among 40- to 49-year-old men (from 12.5% to 11.2%; P = .4). Screening rates significantly declined in men age 50 to 59 years (from 33.2% to 24.8%; P < .01), age 60 to 74 years (from 51.2% to 43.6%; P < .01), and age 75 years or older (from 43.9% to 37.1%; P = .03). A large percentage of men were screened for prostate cancer despite a high risk (> 52%) of 9-year mortality, including approximately one third of men older than age 75 years. Approximately 1.4 million men age 65 years or older with a high risk (> 52%) of 9-year mortality were screened in 2013.
  
  
  CONCLUSIONS
  Prostate cancer screening significantly declined among men older than age 50 years after the 2012 USPSTF guideline discouraging PSA-based screening. A significant proportion of men continue to be screened despite a high risk of 9-year mortality, including one third of men age 75 years and older.
authors.affiliation: All authors: University of Chicago Medical Center, Chicago, IL.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Drazer
authors.affiliation: All authors: University of Chicago Medical Center, Chicago, IL.
authors.forename: Dezheng
authors.initials: D
authors.lastname: Huo
authors.affiliation: All authors: University of Chicago Medical Center, Chicago, IL. seggener@surgery.bsd.uchicago.edu.
authors.forename: Scott E
authors.initials: SE
authors.lastname: Eggener
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D055088:Early Detection of Cancer / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data / Q000639:trends; D019983:Guideline Adherence / Q000706:statistics & numerical data / Q000639:trends; D006306:Health Surveys; D006801:Humans; D007407:Interviews as Topic; D008017:Life Expectancy; D008297:Male; D008403:Mass Screening / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data / Q000639:trends; D011939:Mental Recall; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D012107:Research Design; D012306:Risk; D015983:Selection Bias; D014481:United States / Q000453:epidemiology
chemical_list: D017430:Prostate-Specific Antigen